Alector vs Maze Therapeutics
ALEC and MAZE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALEC and MAZE compare
Maze Therapeutics is the larger company, worth 6.7 times as much as Alector ($1.9B against $284M).
Alector scores higher on the StockData Score (12 against 4 for Maze Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALEC | MAZE |
|---|---|---|
| Size and price | ||
| Market cap | $284M | $1.9B |
| Share price | $2.54 | $34.33 |
| Change, 1 year | 89.6% | 5.4% |
| Change, 5 years | −88.1% | – |
| Beta (5Y) | 1.50 | 0.87 |
| Employees | 103 | 141 |
| StockData Score | ||
| Total score | 12 (better) | 4 |
| Valuation score | 3 (better) | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 3 (better) | 1 |
| Health score | 5 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 7.3× | – |
| P/S | 1.6× | – |
| P/B | 2.4× (better) | 4.4× |
| EV/EBITDA | 3.7× | – |
| FCF yield | −52.9% | −6.0% (better) |
| Fair value | $8.10 | – |
| Margin of safety | 68.6% | – |
| Growth | ||
| Revenue growth (TTM) | 151% | – |
| Revenue growth, 5Y average | −0.05% | – |
| Profitability | ||
| Operating margin | 20.2% | – |
| Net margin | 23.9% | – |
| FCF margin | −86.5% | – |
| Return on equity | 47.5% (better) | −37.5% |
| Return on invested capital | – | −353% |
| Financial health | ||
| Debt / equity | 0.00 | 0.09 (better) |
| Net debt / EBITDA | −3.53 | – |
| Current ratio | 4.10 | 14.14 (better) |
| Altman Z-score | −1.55 | 11.94 (better) |
| Piotroski F-score | 1 | 3 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 85.8% | 105% |
| Held by insiders | 9.6% | 16.9% |
| Insider net buying, 12 months | −$1.0M (better) | −$25.0M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 8.3% | 14.5% |
Go deeper
- ALEC stock overview
- ALEC income statement
- ALEC valuation and score
- MAZE stock overview
- MAZE income statement
- MAZE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.